Founded nine years ago, Cambridge, MA-based Flagship manages over $600 million in early-stage funds and invests in three main sectors: therapeutics, life science tools and diagnostics, and bioenergy/cleantech. The firm usually takes the lead investor spot when financing a funding round, and over 80 percent of the company's investments are seed or first round. During this early round, the firm designs and validates a suitable business model for its portfolio companies; it also secures the initial management team and advisors who can guide the company through the various stages of development. Notable portfolio companies include Acceleron Pharma, BIND Biosciences, Concert Pharmaceuticals and Resolvyx Pharmaceuticals.